Cas:1131587-30-8 Ethyl 2-ethyl-5-iodobenzoate manufacturer & supplier

Chemical Name:Ethyl 2-ethyl-5-iodobenzoate

CAS.NO:1131587-30-8

Synonyms:2-ethyl-5-iodobenzoic acid ethyl ester;ethyl 2-ethyl-5-iodanyl-benzoate

Molecular Formula:C₁₁H₁₃IO₂

Molecular Weight:304.12400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:26.30000

Exact Mass:303.99600

LogP:3.03030

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-ethyl-5-iodobenzoic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 2-ethyl-5-iodanyl-benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 2-ethyl-5-iodanyl-benzoate Use and application,2-ethyl-5-iodobenzoic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good. Ethyl 2-ethyl-5-iodobenzoate manufacturer Secretary of Health Francisco Duque said authorities are working with the Chinese embassy to respectfully handle the remains of the man while following international protocol to contain the disease. Ethyl 2-ethyl-5-iodobenzoate supplier Secretary of Health Francisco Duque said authorities are working with the Chinese embassy to respectfully handle the remains of the man while following international protocol to contain the disease. Ethyl 2-ethyl-5-iodobenzoate vendor At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good. Ethyl 2-ethyl-5-iodobenzoate factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.